Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its third quarter net loss rose 73 percent year over year as it prepares for 2020 launches of two lung cancer tests.

Next year, the firm plans to release a test to noninvasively assess risk in patients with lung nodules and another to predict which patients may need added chemotherapy after surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.